CoChat

Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: This randomized, double-blind, placebo-controlled, multicenter, 2-period crossover study (two 6-week treatment periods separated by a 2-week washout period) evaluated the efficacy and safety of pregabalin (150 to 300 mg/d) for treatment of pain and pain on walking in patients with painful diabetic peripheral neuropathy (DPN) who experienced pain while walking. METHODS: Co-primary efficacy endpoints were: (1) mean pain score (last 7 daily pain diary scores, 0 to 10 numeric rating scale at end of each treatment period) and (2) DPN pain on walking (0 to 10 numeric rating scale immediately after walking 50 feet [15.2 m] on flat surface). Secondary endpoints included other pain parameters, patient-reported sleep, health-related quality of life, and safety measures. RESULTS: Two hundred three patients were treated (pregabalin, n=198; placebo, n=186), with no statistically significant treatment difference for pregabalin versus placebo in the co-primary efficacy endpoints, mean DPN pain (P=0.0656) and mean DPN pain on walking (P=0.412). A carryover effect was observed. Analysis of co-primary endpoints for period 1 showed significant treatment difference for DPN pain (P=0.034) and DPN pain on walking (P=0.001). Treatment with pregabalin resulted in significant improvements versus placebo on prespecified patient global impression of change (end of period 1; P=0.002), and sleep interference rating scale (end of period 2; P=0.011). Adverse events were more frequent with pregabalin than with placebo and caused discontinuation in 13 (6.6%) pregabalin patients versus 5 (2.7%) placebo patients. DISCUSSION: Failure to meet the co-primary objectives may be related to carryover effect from period 1 to period 2, lower pregabalin dose (150 to 300 mg/d), and/or placebo response in painful DPN.

Overview

Integrity signals

Registry

Crossref · 10.1097/ajp.0000000000000198

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 37

Metadata

Authors
Huffman, C., Stacey, B. R., Tuchman, M., Burbridge, C., Li, C., Parsons, B., Pauer, L., Scavone, J. M., Behar, R., & Yurkewicz, L.
Affiliations
  • Oregon Health & Science University (US)
  • Palm Beach Neurological Center (US)
  • Pfizer (United States) (US)
Corresponding author
Huffman, Cynthia
Venue
The Clinical Journal of Pain
Published
2015-11
Volume
31
Issue
11
Pages
946-958
ISSN
0749-8047 (ISSN-L)
OpenAlex
W1981449528
Cited by
37
References
50
Citations by year
2026: 5 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 2 · 2015: 2
FWCI
2.92
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Journal of Pain (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
pregabalin, diabetic neuropathic pain, neuropathic pain, residual effects, sleep interference, health-related quality of life, adverse events, placebo response, dose comparison
MeSH terms
Pregabalin, Adult, Aged, Aged, 80 and over, Analgesics, Diabetic Neuropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Pain, Pain Measurement, Quality of Life, Sleep, Walking, Treatment Outcome, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking. https://app.cochat.ai/papers/10.1097/ajp.0000000000000198
The paper
Huffman, C., Stacey, B. R., Tuchman, M., Burbridge, C., Li, C., Parsons, B., Pauer, L., Scavone, J. M., Behar, R., & Yurkewicz, L. (2015). Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking. The Clinical Journal of Pain. https://doi.org/10.1097/ajp.0000000000000198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.